A number of other research firms have also recently issued reports on AMGN. Mizuho set a $195.00 price objective on Amgen and gave the company a buy rating in a report on Friday, March 10th. Vetr cut Amgen from a hold rating to a sell rating and set a $174.10 price objective for the company. in a report on Monday, March 13th. Piper Jaffray Companies restated an overweight rating and set a $193.00 price objective on shares of Amgen in a report on Tuesday, March 14th. Oppenheimer Holdings Inc. restated an outperform rating and set a $189.00 price objective on shares of Amgen in a report on Tuesday, March 14th. Finally, BMO Capital Markets restated an outperform rating and set a $212.00 price objective on shares of Amgen in a report on Monday, March 6th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. Amgen presently has an average rating of Buy and a consensus target price of $186.89.
Shares of Amgen (NASDAQ:AMGN) traded up 0.9307% during mid-day trading on Monday, reaching $154.4441. The company had a trading volume of 2,524,554 shares. Amgen has a 1-year low of $133.64 and a 1-year high of $184.21. The stock has a market capitalization of $113.58 billion, a price-to-earnings ratio of 14.6698 and a beta of 1.15. The firm has a 50-day moving average price of $161.77 and a 200-day moving average price of $159.14.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.00 by $0.15. Amgen had a return on equity of 29.42% and a net margin of 33.59%. The company had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter in the previous year, the business earned $2.90 EPS. Amgen’s revenue was down 1.1% compared to the same quarter last year. Equities analysts expect that Amgen will post $12.46 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This story was first posted by sleekmoney and is the property of of sleekmoney. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://sleekmoney.com/amgen-inc-amgn-given-a-159-00-price-target-at-leerink-swann/1846505.html.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Wednesday, May 17th will be issued a $1.15 dividend. The ex-dividend date of this dividend is Monday, May 15th. This represents a $4.60 annualized dividend and a yield of 3.01%. Amgen’s dividend payout ratio (DPR) is presently 44.92%.
A number of hedge funds and other institutional investors have recently made changes to their positions in AMGN. Aperio Group LLC increased its position in shares of Amgen by 5.3% in the third quarter. Aperio Group LLC now owns 360,735 shares of the medical research company’s stock valued at $60,174,000 after buying an additional 18,266 shares during the period. Nordea Investment Management AB increased its position in shares of Amgen by 2.0% in the third quarter. Nordea Investment Management AB now owns 5,830,858 shares of the medical research company’s stock valued at $972,645,000 after buying an additional 111,690 shares during the period. Mizuho Trust & Banking Co. Ltd. increased its position in shares of Amgen by 1.0% in the third quarter. Mizuho Trust & Banking Co. Ltd. now owns 1,229,739 shares of the medical research company’s stock valued at $205,133,000 after buying an additional 11,665 shares during the period. BRC Investment Management LLC purchased a new position in shares of Amgen during the third quarter valued at approximately $6,852,000. Finally, Vicus Capital purchased a new position in shares of Amgen during the third quarter valued at approximately $327,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/amgen-inc-amgn-given-a-159-00-price-target-at-leerink-swann/1846505.html
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.